Two Sigma Advisers LP Grows Position in Personalis, Inc. (NASDAQ:PSNL)

Two Sigma Advisers LP lifted its holdings in shares of Personalis, Inc. (NASDAQ:PSNL) by 25.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,300 shares of the company’s stock after buying an additional 7,000 shares during the period. Two Sigma Advisers LP’s holdings in Personalis were worth $198,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. abrdn plc purchased a new position in Personalis in the fourth quarter worth about $1,722,000. Dimensional Fund Advisors LP lifted its position in shares of Personalis by 144.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 410,083 shares of the company’s stock valued at $2,372,000 after buying an additional 242,141 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of Personalis by 53,126.7% during the 4th quarter. BNP Paribas Financial Markets now owns 71,856 shares of the company’s stock valued at $415,000 after buying an additional 71,721 shares in the last quarter. Barclays PLC lifted its position in shares of Personalis by 67.1% during the 4th quarter. Barclays PLC now owns 109,368 shares of the company’s stock valued at $632,000 after buying an additional 43,900 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in shares of Personalis by 144.3% during the 4th quarter. Jane Street Group LLC now owns 401,314 shares of the company’s stock valued at $2,320,000 after buying an additional 237,033 shares in the last quarter. 61.91% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on PSNL. HC Wainwright lifted their target price on Personalis from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, May 7th. Guggenheim started coverage on Personalis in a research note on Thursday, May 15th. They issued a “buy” rating and a $6.00 price objective on the stock. Craig Hallum started coverage on Personalis in a report on Monday, March 17th. They issued a “buy” rating and a $8.00 target price for the company. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $7.00 target price on shares of Personalis in a report on Thursday, April 10th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $7.67.

Personalis Stock Up 3.0%

PSNL opened at $5.21 on Friday. Personalis, Inc. has a 52-week low of $1.14 and a 52-week high of $7.20. The stock has a market cap of $460.17 million, a P/E ratio of -3.10 and a beta of 1.86. The business has a fifty day moving average of $4.13 and a 200 day moving average of $4.48.

Personalis (NASDAQ:PSNL) last issued its earnings results on Tuesday, May 6th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.05. The business had revenue of $20.61 million during the quarter, compared to analysts’ expectations of $17.41 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. Equities analysts anticipate that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.